Yes. Zepbound and Mounjaro are the same molecule, tirzepatide. Both come from Eli Lilly. Both run the same weekly ladder, 2.5 mg up to 15 mg [4] [5]. What differs is the label and the price. Mounjaro is approved to improve blood sugar in type 2 diabetes and reduce cardiovascular risk in certain adults with type 2 diabetes. Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. On November 12, 2026, LillyDirect listed self-pay from $499 per month for Mounjaro and $299 per 28 days for the lowest-strength Zepbound KwikPen, subject to terms [9] [10].
An insurer may cover one brand and exclude the other. The GLP-1 insurance coverage guide explains how formularies, diagnoses and prior authorization can affect what a plan pays.
What the two labels say
Mounjaro is approved, with diet and exercise, to improve blood sugar in adults and children aged 10 and older with type 2 diabetes. The maximum pediatric dose for blood sugar control is 10 mg weekly. The separate cardiovascular indication covers adults with type 2 diabetes who are at high risk of major cardiovascular events: cardiovascular death, nonfatal heart attack or nonfatal stroke [5].
Zepbound is approved to reduce excess body weight and maintain weight loss long term in adults with obesity or overweight with at least one weight-related condition. The tirzepatide sleep apnea trials support its separate approval for moderate-to-severe obstructive sleep apnea in adults with obesity. Neither indication requires diabetes [4].
The adult dosing schedules start at 2.5 mg weekly and increase in 2.5 mg steps after at least four weeks when indicated. The adult maximum is 15 mg weekly for both brands [4] [5]. The Zepbound dose guide explains the weight-management maintenance choices of 5, 10 or 15 mg. The label lists 10 or 15 mg for sleep apnea [4].
Two trial programs, one molecule
Each label rests on its own trials. Zepbound’s weight label leans on SURMOUNT-1. That trial enrolled 2,539 adults without diabetes for 72 weeks [1]. Weight fell 15.0% on 5 mg. It fell 19.5% on 10 mg and 20.9% on 15 mg. Placebo lost 3.1% [1].
Mounjaro’s program measured blood sugar first. SURPASS-2 randomized 1,879 people with type 2 diabetes for 40 weeks [2]. HbA1c fell 2.01 to 2.30 percentage points on tirzepatide. It fell 1.86 points on semaglutide 1 mg [2]. Weight loss beat semaglutide by 1.9 kg to 5.5 kg, depending on dose [2].
Over 72 weeks, SURMOUNT-2 compared tirzepatide with placebo in 938 adults with overweight or obesity and type 2 diabetes. Mean weight fell 12.8% on 10 mg, 14.7% on 15 mg and 3.2% with placebo [3]. That is lower than in SURMOUNT-1. The people differed, so this is a comparison across trials with different populations and cannot identify a brand effect.
What self-pay prices cover
Lilly defines list price as its price to wholesalers. A pharmacy price depends on insurance, savings eligibility, and the product and pharmacy on the prescription [6] [7].
LillyDirect listed the Mounjaro single-dose pen from $499 per month at all six strengths on November 14, 2026. A prescription is required, and taxes or fees may apply [10]. The Zepbound KwikPen starts at $299 per 28 days at 2.5 mg and $399 at 5 mg. At 7.5 mg and above, the first eligible purchase costs $449 per 28 days. Keeping that price requires purchasing each refill within 45 days of the previous delivery. Without a timely refill, LillyDirect lists $499 for 7.5 mg and $699 for 10, 12.5 and 15 mg. Pen needles cost extra [9] [11].
The savings cards are separate from these cash offers. Eligible Zepbound patients whose commercial insurance covers the single-dose pen may pay as little as $25, subject to the program terms [11]. Mounjaro advertises a separate savings card tier from $499 per one-month single-dose pen fill for eligible patients with commercial insurance that does not cover it and a prescription for an approved use [8].
Why brand-level results can differ
A separate records study of weight loss by brand found that a greater share of Zepbound users lost more than 15% of their starting weight than Mounjaro users. Dose and patient characteristics may help explain the difference, but the study could not determine how much each contributed [12].
A similar label distinction applies to Wegovy and Ozempic, which share semaglutide and have different approved uses. Compounded tirzepatide is distinct from the two FDA-approved brands discussed here.